<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor progesterone receptors and lack overexpression of human epidermal growth factor receptor. As no hormone therapy can be implemented, chemotherapy remains the main weapon. Nowadays, widely available chemo regimens for TNBC treatment can consist of anthracyclines, taxanes, antimetabolites, or platinums, but all of the aforementioned are highly toxic to the bone marrow, liver, kidneys, and nervous system. Targeted treatment using nanotechnology seems to be a ray of hope in impeding this morbid disease.</p>
</abstract>

Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor progesterone receptors and lack overexpression of human epidermal growth factor receptor. As no hormone therapy can be implemented, chemotherapy remains the main weapon. Nowadays, widely available chemo regimens for TNBC treatment can consist of anthracyclines, taxanes, antimetabolites, or platinums, but all of the aforementioned are highly toxic to the bone marrow, liver, kidneys, and nervous system. Targeted treatment using nanotechnology seems to be a ray of hope in impeding this morbid disease.

Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Department of Nephrology, Transplantology and Internal Medicine

Pomeranian Journal of Life Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor...

Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Pubblicato online: 22 apr 2022

Pagine: 25 - 27

DOI: https://doi.org/10.21164/pomjlifesci.792

Parole chiave
triple negative breast cancer, nanotechnology, nanoparticles, oncology

© 2022 Wiktoria Feret, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Pubblicato online: 22 apr 2022

Pagine: 25 - 27

DOI: https://doi.org/10.21164/pomjlifesci.792

Parole chiavetriple negative breast cancer, nanotechnology, nanoparticles, oncology

© 2022 Wiktoria Feret, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
triple negative breast cancer, nanotechnology, nanoparticles, oncology